- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
ARS Pharmaceuticals, based in San Diego, submitted a generic product application requiring FDA approval.
1 report, 1 independent
Updated Sep 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ARS Pharmaceuticals, based in San Diego, submitted a generic product application requiring FDA approval.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Generic medicine services are seeking approval for launch from the FDA.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- FDA and state authorities are investigating product manufacturers in Utah.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
Coverage
Newest first; wire copies grouped- Insider MonkeyARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDA ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is among the fastest growing small cap stocks to buy. Lupin Inc., a leading player in the heal